Germany-based Evela Health has completed a €2 million funding round to expand its evidence-based menopause care platform, addressing a critical gap in healthcare for women over 40. The round combines investment from Impact Shakers, BetterVentures, various angel investors, and €1.2 million in non-dilutive funding from IBB Berlin.
Founded 18 months ago by three healthcare and technology veterans, Evela Health is tackling what Co-CEO Dr. Valerie Kirchberger calls “a phase of life that desperately needs expertise, knowledge, and proper care.”
Addressing a Critical Healthcare Gap
Traditional gynecologists, constrained by 5-minute appointment slots and €16 reimbursements in Germany, lack the time needed for comprehensive menopause discussions. This creates a healthcare void during a transition that affects every woman and involves over 34 distinct symptoms.
“Doctors are not negligent due to their personalities – they simply lack sufficient time and often training,” explains Dr. Kirchberger, a trained pediatrician with management experience at Charité hospital in Berlin. “It is impossible to address the multiple dimensions affected by menopause within the time allocated for routine screenings.”
The time constraints have created a market flooded with misinformation and ineffective products. Women struggle to find evidence-based guidance while navigating everything from unproven topical treatments to persistent misconceptions about hormone therapy based on outdated research.
A Comprehensive Platform Solution
Evela Health has developed a digital platform built around ten key life dimensions affected by menopause, including sleep, nutrition, mental health, and sexual health. This framework enables targeted interventions based on individual needs assessment.
The platform combines three core components: Evela Campus, a knowledge base addressing menopause-related symptoms that many women don’t recognize as hormone-related; personalized consultations with trained menopause specialists who dedicate substantial time to understanding each woman’s challenges; and ongoing support through webinars, follow-ups, and lifestyle implementation guidance.
Unlike traditional medical appointments, these consultations begin with comprehensive questionnaires and are conducted by trained counselors rather than doctors. This approach allows for in-depth discussions that provide validation, evidence-based information, and empowerment to seek appropriate medical treatment when needed.In parallel, Evela is developing tools to complement these consultations with wearable health data and AI-driven analysis, creating a more comprehensive and continuously updated picture of each woman’s health journey.
“We create individualized consultation plans addressing the dimensions where issues are most acute,” Dr. Kirchberger notes. “Menopause extends far beyond hormonal considerations and treatments.”
Market Approach and Early Success
While Evela Health offers direct consumer access, the company is focused on B2B2C channels through employers and insurance providers to ensure broad accessibility. This strategy addresses significant workplace challenges, as women over 40 often experience increased sick leave and reduced working hours starting during perimenopause despite representing highly skilled workers.
The company has secured contracts with business customers among them insurance provider HanseMerkur, with additional partnerships in the pipeline. These early successes validate their approach to treating menopause as both a healthcare priority and economic imperative.
“Our mission involves making evidence-based menopause care available for everyone,” emphasizes Dr. Kirchberger. “This demographic represents incredibly valuable, knowledgeable workers whose support benefits both the individuals and organizations.”
The founding team combines medical expertise, business scaling experience, and research depth. Dr. Valerie Kirchberger brings clinical training and startup experience from Heartbeat Medical. Eva-Maria Meijnen contributes business operations expertise from corporate consulting and a successful exit at dental technology startup PlusDental. Dr. Cornelius Remschmidt oversees medical and scientific aspects with his internal medicine background and research experience at Robert Koch Institute and Charité.
This multidisciplinary approach positions the company to address both technical healthcare challenges and practical implementation across diverse organizational systems.
Scaling for Impact
The fresh funds will primarily support strategic team expansion focused on tech and AI expertise, sales execution and platform development. Currently serving primarily perimenopausal women in the German-speaking market, Evela Health eventually plans broader European expansion as they establish their evidence-based care model. The funding positions them to demonstrate product-market fit across multiple channels while preparing for future scaling.
With menopause affecting 50% of the population yet receiving inadequate medical attention, Evela Health’s platform treats this universal life phase as a healthcare priority requiring specialized expertise and dedicated time – resources that traditional systems often cannot provide today.
